131 related articles for article (PubMed ID: 38495484)
1. A Retrospective Analysis of Azvudine in Patients with COVID-19 and Pre-existing Cancer.
Li F; Zheng K; Qi X; Cui K; Yang J; Hao Z
J Cancer; 2024; 15(8):2442-2447. PubMed ID: 38495484
[No Abstract] [Full Text] [Related]
2. Effectiveness of azvudine against severe outcomes among hospitalized COVID-19 patients in Xinjiang, China: a single-center, retrospective, matched cohort study.
Kapar A; Xie S; Guo Z; Nan Y; Du Y; Yin X; Gong T; Gu X; Zhou Y; Lu W; Yang A; Luo Z; Dai J; Wang K; Zhao S; Wang K
Expert Rev Anti Infect Ther; 2024 May; ():. PubMed ID: 38822541
[TBL] [Abstract][Full Text] [Related]
3. Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study.
Sun Y; Jin L; Dian Y; Shen M; Zeng F; Chen X; Deng G
EClinicalMedicine; 2023 May; 59():101981. PubMed ID: 37193346
[TBL] [Abstract][Full Text] [Related]
4. Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world study.
Wang S; Sun J; Zhang X; Li M; Qin B; Liu M; Zhang N; Wang S; Zhou T; Zhang W; Ma C; Deng X; Bai Y; Qu G; Liu L; Shi H; Zhou B; Li K; Yang B; Li S; Wang F; Ma J; Zhang L; Wang Y; An L; Liu W; Chang Q; Zhang R; Yin X; Yang Y; Ao Q; Ma Q; Yan S; Huang H; Song P; Gao L; Lu W; Xu L; Lei L; Wang K; Zhang Q; Song Q; Zhang Z; Fang X; He Y; Li T; Zhu P
EClinicalMedicine; 2024 Mar; 69():102468. PubMed ID: 38361990
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study.
Zhao X; Cheng Y; Zhang M; Qianda B; Zhouma B; Yangzhen B; Zheng Y; Zhang S; Zhao H
Infect Drug Resist; 2023; 16():6053-6060. PubMed ID: 37719651
[TBL] [Abstract][Full Text] [Related]
6. Real-world effectiveness of molnupiravir, azvudine and paxlovid against mortality and viral clearance among hospitalized patients with COVID-19 infection during the omicron wave in China: A retrospective cohort study.
Chen Y; Lin Y; Lu H; Wu X; Pan Y; Xia A; Pang L; Ye W; Xu F
Diagn Microbiol Infect Dis; 2024 May; 109(4):116353. PubMed ID: 38776665
[TBL] [Abstract][Full Text] [Related]
7. Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study.
Han X; Gao D; Li C; Yuan X; Cui J; Zhao W; Xie F; Wang K; Liu Y; Muo G; Xi N; Zheng M; Wang R; Xiao K; Zhao D; Zhang X; Han X; Wang B; Zhang T; Xie W; Xie L
BMC Infect Dis; 2024 Jan; 24(1):57. PubMed ID: 38191304
[TBL] [Abstract][Full Text] [Related]
8. Azvudine for the Treatment of COVID-19 in Pre-Existing Cardiovascular Diseases: A Single-Center, Real-World Experience.
Wu L; He ZH; Huang L; Guo X; Li XY; Zhang HD; Chen MH
Adv Sci (Weinh); 2024 Mar; ():e2306050. PubMed ID: 38544344
[TBL] [Abstract][Full Text] [Related]
9. Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study.
Zhao Q; Zheng B; Han B; Feng P; Xia Z; Jiang H; Ying Y; Zhu J; Fei C; Xiang J; Shen L; Luo Q; Wu Y; Wusiman A; Xin C; Zhang M; Li G; Li X
Infect Dis Ther; 2023 Aug; 12(8):2087-2102. PubMed ID: 37486556
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
11. All-cause mortality in moderate and severe COVID-19 patients with myocardial injury receiving versus not receiving azvudine: a propensity score-matched analysis.
Chen R; Guo Y; Deng S; Wang J; Gao M; Han H; Wang L; Jiang H; Huang K
Cardiol Plus; 2023; 8(2):103-110. PubMed ID: 37539021
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Azvudine and Nirmatrelvir/Ritonavir and Combined Use in Patients with COVID-19.
Hu CY; Cui WS; Lei Y; Tang YW; Zhang YY; Su QM; Peng F; Zeng YF; Song JL; Luo CN; Zhou Y; Li XY; Zhao ZX
Infect Drug Resist; 2023; 16():7797-7808. PubMed ID: 38148771
[TBL] [Abstract][Full Text] [Related]
13. Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: A retrospective cohort study.
Deng G; Li D; Sun Y; Jin L; Zhou Q; Xiao C; Wu Q; Sun H; Dian Y; Zeng F; Pan P; Shen M
J Med Virol; 2023 Apr; 95(4):e28756. PubMed ID: 37185838
[TBL] [Abstract][Full Text] [Related]
14. Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study.
Chen MP; Jiang DX; Rang JX; Zhuo HB; Zhou ZG
Sci Rep; 2024 Feb; 14(1):3318. PubMed ID: 38337014
[TBL] [Abstract][Full Text] [Related]
15. Oral azvudine for mild-to-moderate COVID-19 in high risk, nonhospitalized adults: Results of a real-world study.
Yang H; Wang Z; Jiang C; Zhang Y; Zhang Y; Xu M; Zhang Y; Wang Y; Liu X; An Z; Tong Z
J Med Virol; 2023 Jul; 95(7):e28947. PubMed ID: 37470209
[TBL] [Abstract][Full Text] [Related]
16. Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching.
Wei AH; Zeng L; Wang L; Gui L; Zhang WT; Gong XP; Li J; Liu D
Front Pharmacol; 2023; 14():1274294. PubMed ID: 37900159
[No Abstract] [Full Text] [Related]
17. Lactate dehydrogenase predicts disease progression outcome in COVID-19 patients treated with Azvudine.
Mao M; Dian Y; Sun Y; Chen W; Zhu W; Deng G
Front Cell Infect Microbiol; 2023; 13():1237277. PubMed ID: 37920449
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety evaluation of Azvudine in the prospective treatment of COVID-19 based on four phase III clinical trials.
Zhu KW
Front Pharmacol; 2023; 14():1228548. PubMed ID: 37693894
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19: a retrospective observational study.
Zhou Z; Zheng H; Xiao G; Xie X; Rang J; Peng D
BMC Infect Dis; 2024 Jan; 24(1):47. PubMed ID: 38177982
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory predictors (eosinophil, C-RP and IL-6) and effectiveness of oral Azvudine tablets treatment in COVID-19 hospitalized patients: A retrospective, self-controlled study.
Zhao Y; Gao G; Li W; Xu Z; Wang X; Chang R
Heliyon; 2023 Nov; 9(11):e21941. PubMed ID: 38034620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
